Search hospitals > New Jersey > Newark
Saint Michael's Medical Center
Claim this profileNewark, New Jersey 07102
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in AIDS
Conducts research for HIV/AIDS
Conducts research for Infections
Conducts research for HIV
103 reported clinical trials
1 medical researcher
Summary
Saint Michael's Medical Center is a medical facility located in Newark, New Jersey. This center is recognized for care of Human Immunodeficiency Virus Infection, AIDS, HIV/AIDS, Infections, HIV and other specialties. Saint Michael's Medical Center is involved with conducting 103 clinical trials across 79 conditions. There are 1 research doctors associated with this hospital, such as Jihad Slim, MD.Top PIs
Clinical Trials running at Saint Michael's Medical Center
HIV
Infections
Human Immunodeficiency Virus Infection
COVID-19
Coronavirus
Pneumonia
Community-acquired Pneumonia
Contagious Diseases
Immune Deficiency Syndrome
HIV/AIDS
B/F/TAF Oral Therapy
for HIV
The goal of this clinical study is to learn how safe and effective it is to switch to an oral therapy of Bictegravir/Emtricitabine/Tenofovir (B/F/TAF) from Cabotegravir + Rilpivirine (CAB+RPV) in participants living with virologically suppressed human immunodeficiency virus type 1 (HIV-1), meaning participants with HIV RNA levels below detectable levels. The primary objective of this study is to assess the safety of switching to B/F/TAF in virologically suppressed participants unable/unwilling to continue on CAB+RPV intramuscular (IM) injections or wishing to switch to oral therapy through Week 12.
Recruiting3 awards Phase 47 criteria
DOR/ISL
for HIV
This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of doravirine/islatravir (DOR/ISL [MK-8591A]) in treatment-naïve participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that DOR/ISL is non-inferior to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) <50 copies/mL at Week 48.
Recruiting1 award Phase 3
Bictegravir + Lenacapavir
for HIV
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC in people living with HIV-1 (PWH). The primary objective of this study is to learn how effective it is to switch to BIC/LEN FDC tablets versus continuing on B/F/TAF FDC tablets in virologically suppressed PWH.
Recruiting1 award Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Saint Michael's Medical Center?
Saint Michael's Medical Center is a medical facility located in Newark, New Jersey. This center is recognized for care of Human Immunodeficiency Virus Infection, AIDS, HIV/AIDS, Infections, HIV and other specialties. Saint Michael's Medical Center is involved with conducting 103 clinical trials across 79 conditions. There are 1 research doctors associated with this hospital, such as Jihad Slim, MD.